Beiersdorf and Insilico join forces on AI research

Companies collaborate to discover novel, safe bioactive ingredients for skin indications – applying AI to advanced cosmetics: An important part of the Longevity ecosystem.

Skin care giant Beiersdorf and AI firm Insilico Medicine have announced a collaboration to jointly discover novel, safe bioactive ingredients for a specific skin indication to serve as the basis for developing appropriate skincare products. Hamburg-based Beiersdorf is best known for its Nivea consumer skincare brand.

“As part of our Open Innovation culture, we are always looking for new technologies and partners with strengths that complement ours,” said Dr. May Shana’a, Senior Corporate Vice President, Research and Development, at Beiersdorf. “We are delighted to now be working with Insilico Medicine as a veritable expert when it comes to artificial intelligence. We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biological effects in silico. This enables us to cater even better to the consumers’ as yet unmet skincare needs.”

As part of the collaboration, new molecules for a specific skin indication are to be generated and analyzed using next-generation artificial intelligence developed by Insilico.

“We firmly believe there is a great potential in this collaboration,” said Alex Zhavoronkov, CEO of Insilico Medicine. “We worked with many consumer companies in the past and in my opinion, Beiersdorf became an undisputed leader in the area of skin research as well as in digital technologies in recent decades. We are delighted that they have recognized the potential of artificial intelligence early on and hope to demonstrate the power of AI going forward in our collaboration.”

We believe that Advanced Cosmetics will become an important part of the Longevity ecosystem, and the sector was included by Aging Analytics Agency as part of its 2019 Longevity Industry Landscape Overview. Forthcoming Longevity-centric developments in the world of cosmetics are expected to include rejuvenated stem cell facelifts, personalised stem cell creams and prognostics, and cosmetic nutraceuticals targeted at the hallmarks of aging.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

Insurer puts down £20m to research an aging rethink

A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society. The world is...

23andMe redundancies: DNA test market decline?

Could layoffs at 23andMe be a sign that the consumer appetite for genetic testing is declining? We expect consumer markets to transition to more...

Singapore agetech – ones to watch in 2020

Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.